Kerberos Proximal Solutions Inc.

by Robert Neil The growth of markets within Asia is creating an enticing lure for medical device, pharmaceutical, and biomedical companies seeking to establish or enhance their presence in the region.

Investors love to remind everyone that IPOs are financing events, not exiting events, using the mantra to put off Judgment Day for their investments. So how have device companies fared after the recen

Because the technology risks of medical device development are so much lower than those of, say, biotech, most venture capital firms can afford to invest as early as possible. And since exits also ten

What's the value of a well-documented set of clinical samples in the atherosclerosis business? For Merck, about $150 million. For FoxHollow, funding and validation for its contrarian device model. by